Neurological; Disorder, Nervous System Clinical Trial
Official title:
Autologous Bone Marrow Mononuclear Cell Therapy for Incurable Neurological Disorders
| Verified date | October 2018 |
| Source | Neurogen Brain and Spine Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of the study was to analyze the benefit of autologous mononuclear cell therapy in incurable neurological disorders.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | December 2018 |
| Est. primary completion date | June 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 6 Months to 80 Years |
| Eligibility |
Inclusion Criteria: - diagnosed cases of incurable neurological disorders - age above 6 months Exclusion Criteria: - presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus - malignancies - bleeding tendencies - pneumonia - renal failure - severe liver dysfunction - severe anemia [Hemoglobin < 8] - any bone marrow disorder - space occupying lesion in brain - other acute medical conditions such as respiratory infection and pyrexia - pregnancy - lactation |
| Country | Name | City | State |
|---|---|---|---|
| India | Neurogen brain and spine institute | Navi Mumbai | Maharashtra |
| Lead Sponsor | Collaborator |
|---|---|
| Neurogen Brain and Spine Institute |
India,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in various clinical symptoms of neurological disorders | Change in various symptoms such as muscle strength, limb strength, ambulation, neck holding, bladder bowel management, spasticity, sensation, speech, etc depending on the disorder will be recorded at 1 year follow up. Percentage analysis of each symptom will be carried out to study the benefits of stem cell therapy on them. | 1 year |